|
US7235537B2
(en)
*
|
2002-03-13 |
2007-06-26 |
Array Biopharma, Inc. |
N3 alkylated benzimidazole derivatives as MEK inhibitors
|
|
KR100984595B1
(ko)
|
2002-03-13 |
2010-09-30 |
어레이 바이오파마 인크. |
Ｍｅｋ 억제제로서의 ｎ3 알킬화 벤즈이미다졸 유도체
|
|
ES2331246T3
(es)
|
2003-07-24 |
2009-12-28 |
Warner-Lambert Company Llc |
Derivados de benzamidazol como inhibidores del mek.
|
|
US7538120B2
(en)
|
2003-09-03 |
2009-05-26 |
Array Biopharma Inc. |
Method of treating inflammatory diseases
|
|
US7144907B2
(en)
*
|
2003-09-03 |
2006-12-05 |
Array Biopharma Inc. |
Heterocyclic inhibitors of MEK and methods of use thereof
|
|
WO2005028447A1
(en)
|
2003-09-22 |
2005-03-31 |
S*Bio Pte Ltd |
Benzimidazole derivates: preparation and pharmaceutical applications
|
|
US7732616B2
(en)
*
|
2003-11-19 |
2010-06-08 |
Array Biopharma Inc. |
Dihydropyridine and dihydropyridazine derivatives as inhibitors of MEK and methods of use thereof
|
|
CN1905873A
(zh)
|
2003-11-19 |
2007-01-31 |
阵列生物制药公司 |
Mek的杂环抑制剂及其使用方法
|
|
US7517994B2
(en)
*
|
2003-11-19 |
2009-04-14 |
Array Biopharma Inc. |
Heterocyclic inhibitors of MEK and methods of use thereof
|
|
NZ590160A
(en)
*
|
2003-11-21 |
2012-07-27 |
Array Biopharma Inc |
AKT protein kinase inhibitors
|
|
US20050171182A1
(en)
*
|
2003-12-11 |
2005-08-04 |
Roger Briesewitz |
Methods and compositions for use in the treatment of mutant receptor tyrosine kinase driven cellular proliferative diseases
|
|
ZA200703912B
(en)
|
2004-10-20 |
2008-09-25 |
Serono Lab |
3-arylamino pyridine derivatives
|
|
EP1828184B1
(en)
*
|
2004-12-01 |
2009-09-16 |
Merck Serono SA |
[1,2,4]triazolo[4,3-a]pyridine derivatives for the treatment of hyperproliferative diseases
|
|
ES2405785T3
(es)
|
2005-05-18 |
2013-06-03 |
Array Biopharma Inc. |
Inhibidores heterocíclicos de MEK y métodos de uso de los mismos
|
|
CA2612419C
(en)
|
2005-06-23 |
2017-06-13 |
Array Biopharma Inc. |
Process for preparing benzimidazole compounds
|
|
US8101799B2
(en)
|
2005-07-21 |
2012-01-24 |
Ardea Biosciences |
Derivatives of N-(arylamino) sulfonamides as inhibitors of MEK
|
|
SI1934174T1
(sl)
*
|
2005-10-07 |
2011-08-31 |
Exelixis Inc |
Inhibitorji MEK in postopki za njihovo uporabo
|
|
WO2007071951A1
(en)
*
|
2005-12-21 |
2007-06-28 |
Astrazeneca Ab |
Tosylate salt of 6- (4-br0m0-2-chl0r0phenylamin0) -7-fluoro-n- (2-hydroxyethoxy) -3-methyl-3h-benzimi dazole- 5 - carboxamide , mek inhibitor useful in the treatment of cancer
|
|
GB0601962D0
(en)
|
2006-01-31 |
2006-03-15 |
Ucb Sa |
Therapeutic agents
|
|
ATE523499T1
(de)
|
2006-07-06 |
2011-09-15 |
Array Biopharma Inc |
Cyclopenta [d]-pyrimidine als akt-proteinkinasehemmer
|
|
ATE532789T1
(de)
|
2006-07-06 |
2011-11-15 |
Array Biopharma Inc |
Dihydrothienopyrimidine als akt-proteinkinase- inhibitoren
|
|
US8063050B2
(en)
*
|
2006-07-06 |
2011-11-22 |
Array Biopharma Inc. |
Hydroxylated and methoxylated pyrimidyl cyclopentanes as AKT protein kinase inhibitors
|
|
CA2656566C
(en)
|
2006-07-06 |
2014-06-17 |
Array Biopharma Inc. |
Dihydrofuro pyrimidines as akt protein kinase inhibitors
|
|
ES2528797T3
(es)
*
|
2006-08-21 |
2015-02-12 |
Genentech, Inc. |
Compuestos de aza-benzotiofenilo y métodos de uso
|
|
ZA200901009B
(en)
*
|
2006-08-21 |
2010-05-26 |
Genentech Inc |
Aza-benzothiophenyl compounds and methods of use
|
|
AU2007286808B2
(en)
*
|
2006-08-21 |
2012-12-06 |
Genentech, Inc. |
Aza-benzofuranyl compounds and methods of use
|
|
PL2101759T3
(pl)
|
2006-12-14 |
2019-05-31 |
Exelixis Inc |
Sposoby stosowania inhibitorów MEK
|
|
JO2985B1
(ar)
|
2006-12-20 |
2016-09-05 |
Takeda Pharmaceuticals Co |
مثبطات كينازmapk/erk
|
|
JP5580735B2
(ja)
|
2007-06-12 |
2014-08-27 |
ジェネンテック， インコーポレイテッド |
Ｎ−置換アザインドール類及び使用方法
|
|
CN101918373B
(zh)
|
2007-07-05 |
2013-06-05 |
阵列生物制药公司 |
作为akt蛋白激酶抑制剂的嘧啶基环戊烷
|
|
US8846683B2
(en)
|
2007-07-05 |
2014-09-30 |
Array Biopharma, Inc. |
Pyrimidyl cyclopentanes as Akt protein kinase inhibitors
|
|
US9409886B2
(en)
|
2007-07-05 |
2016-08-09 |
Array Biopharma Inc. |
Pyrimidyl cyclopentanes as AKT protein kinase inhibitors
|
|
WO2009006567A2
(en)
|
2007-07-05 |
2009-01-08 |
Array Biopharma Inc. |
Pyrimidyl cyclopentanes as akt protein kinase inhibitors
|
|
GB0714384D0
(en)
|
2007-07-23 |
2007-09-05 |
Ucb Pharma Sa |
theraputic agents
|
|
ES2456966T3
(es)
|
2007-11-12 |
2014-04-24 |
Takeda Pharmaceutical Company Limited |
Inhibidores de MAPK/ERK cinasa
|
|
US8293763B2
(en)
|
2007-12-19 |
2012-10-23 |
Genentech, Inc. |
8-anilinoimidazopyridines and their use as anti-cancer and/or anti-inflammatory agents
|
|
JP5421925B2
(ja)
*
|
2007-12-19 |
2014-02-19 |
ジェネンテック， インコーポレイテッド |
５−アニリノイミダゾピリジン及び使用の方法
|
|
CA2708176A1
(en)
|
2007-12-21 |
2009-07-02 |
Genentech, Inc. |
Azaindolizines and methods of use
|
|
ES2422733T3
(es)
*
|
2008-01-09 |
2013-09-13 |
Array Biopharma Inc |
Pirimidilciclopentanos hidroxilados como inhibidores de proteínas cinasas AKT
|
|
EP2240455B1
(en)
|
2008-01-09 |
2012-12-26 |
Array Biopharma, Inc. |
Hydroxylated pyrimidyl cyclopentane as akt protein kinase inhibitor
|
|
EP2240494B1
(en)
|
2008-01-21 |
2016-03-30 |
UCB Biopharma SPRL |
Thieno-pyridine derivatives as mek inhibitors
|
|
GB0811304D0
(en)
|
2008-06-19 |
2008-07-30 |
Ucb Pharma Sa |
Therapeutic agents
|
|
ES2426096T3
(es)
|
2008-07-01 |
2013-10-21 |
Genentech, Inc. |
Derivados de isoindolona como inhibidores de la quinasa MEK y métodos de utilización
|
|
US8841462B2
(en)
|
2008-07-01 |
2014-09-23 |
Robert A. Heald |
Bicyclic heterocycles as MEK kinase inhibitors
|
|
HRP20160044T1
(hr)
|
2008-08-04 |
2016-02-26 |
Merck Patent Gmbh |
Novi spojevi fenilamino izonikotinamida
|
|
US8993630B2
(en)
|
2008-11-10 |
2015-03-31 |
Bayer Intellectual Property Gmbh |
Substituted sulphonamido phenoxybenzamides
|
|
WO2010068738A1
(en)
|
2008-12-10 |
2010-06-17 |
Dana-Farber Cancer Institute, Inc. |
Mek mutations conferring resistance to mek inhibitors
|
|
EP2491014A1
(en)
|
2009-10-21 |
2012-08-29 |
Bayer Pharma Aktiengesellschaft |
Substituted halophenoxybenzamide derivatives
|
|
US20120269803A1
(en)
|
2009-10-21 |
2012-10-25 |
Bayer Intellectual Property Gmbh |
Substituted benzosulphonamides
|
|
EP2491015A1
(en)
|
2009-10-21 |
2012-08-29 |
Bayer Pharma Aktiengesellschaft |
Substituted benzosulphonamides
|
|
ES2576061T3
(es)
|
2010-02-25 |
2016-07-05 |
Dana-Farber Cancer Institute, Inc. |
Mutaciones de BRAF que confieren resistencia a inhibidores de BRAF
|
|
BR112012022801B8
(pt)
|
2010-03-09 |
2019-10-29 |
Dana Farber Cancer Inst Inc |
método de identificar um indivíduo que tem câncer que é provável beneficiar-se do tratamento com uma terapia de combinação com um inibidor de raf e um segundo inibidor e uso de um inibidor de raf e um segundo inibidor para a fabricação de um medicamento para tratar câncer
|
|
MY170236A
(en)
|
2010-10-06 |
2019-07-11 |
Glaxosmithkline Llc |
Benzimidazole derivatives as pi3 kinase inhibitors
|
|
WO2012055953A1
(en)
|
2010-10-29 |
2012-05-03 |
Bayer Pharma Aktiengesellschaft |
Substituted phenoxypyridines
|
|
RU2013148817A
(ru)
|
2011-04-01 |
2015-05-10 |
Дженентек, Инк. |
Комбинации соединений-ингибиторов акт и мек и способы их применения
|
|
WO2012135781A1
(en)
|
2011-04-01 |
2012-10-04 |
Genentech, Inc. |
Combinations of akt inhibitor compounds and chemotherapeutic agents, and methods of use
|
|
EP2714037B1
(en)
|
2011-05-25 |
2016-07-13 |
Université Paris Descartes |
Erk inhibitors for use in treating spinal muscular atrophy
|
|
WO2013082511A1
(en)
|
2011-12-02 |
2013-06-06 |
Genentech, Inc. |
Methods for overcoming tumor resistance to vegf antagonists
|
|
CN103204825B
(zh)
|
2012-01-17 |
2015-03-04 |
上海科州药物研发有限公司 |
作为蛋白激酶抑制剂的苯并噻唑化合物及其制备方法和用途
|
|
US20150141470A1
(en)
|
2012-05-08 |
2015-05-21 |
The Broad Institute, Inc. |
Diagnostic and treatment methods in patients having or at risk of developing resistance to cancer therapy
|
|
JP2015527874A
(ja)
|
2012-05-31 |
2015-09-24 |
バイエル ファーマ アクチエンゲゼルシャフト |
肝細胞癌（ｈｃｃ）患者の治療の有効な応答を決定するためのバイオマーカー
|
|
KR102204520B1
(ko)
|
2012-10-12 |
2021-01-20 |
엑셀리시스, 인코포레이티드 |
암의 치료에 사용하기 위한 화합물의 신규 제조 방법
|
|
MA38522A1
(fr)
|
2013-03-21 |
2017-10-31 |
Novartis Ag |
Thérapie de combinaison comprenant un inhibiteur de b-raf et un second inhibiteur.
|
|
EP3043822A1
(en)
|
2013-09-11 |
2016-07-20 |
The J. David Gladstone Institutes, A Testamentary Trust Established under The Will of J. David Gladstone |
Compositions for preparing cardiomyocytes
|
|
CN105384754B
(zh)
*
|
2014-09-02 |
2018-04-20 |
上海科州药物研发有限公司 |
作为蛋白激酶抑制剂的杂环类化合物及其制备方法和用途
|
|
WO2017033113A1
(en)
|
2015-08-21 |
2017-03-02 |
Acerta Pharma B.V. |
Therapeutic combinations of a mek inhibitor and a btk inhibitor
|
|
AR108257A1
(es)
|
2016-05-02 |
2018-08-01 |
Mei Pharma Inc |
Formas polimórficas de 3-[2-butil-1-(2-dietilamino-etil)-1h-bencimidazol-5-il]-n-hidroxi-acrilamida y usos de las mismas
|
|
EP3712133B1
(en)
|
2017-11-14 |
2025-12-24 |
Shenzhen TargetRx, Inc. |
Substituted benzimidazole compound and composition comprising same
|
|
EA202192575A1
(ru)
|
2019-03-21 |
2022-01-14 |
Онксео |
Соединения dbait в сочетании с ингибиторами киназ для лечения рака
|
|
CN114761006A
(zh)
|
2019-11-08 |
2022-07-15 |
Inserm(法国国家健康医学研究院) |
对激酶抑制剂产生耐药性的癌症的治疗方法
|
|
WO2021148581A1
(en)
|
2020-01-22 |
2021-07-29 |
Onxeo |
Novel dbait molecule and its use
|
|
US12280055B2
(en)
|
2021-05-27 |
2025-04-22 |
Mirati Therapeutics, Inc. |
Combination therapies
|
|
TW202342018A
(zh)
|
2022-03-04 |
2023-11-01 |
美商奇奈特生物製藥公司 |
Mek激酶抑制劑
|
|
WO2025073765A1
(en)
|
2023-10-03 |
2025-04-10 |
Institut National de la Santé et de la Recherche Médicale |
Methods of prognosis and treatment of patients suffering from melanoma
|